MedTrace Logo

Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation

NCT07747948 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-08-05

No results posted yet for this study

Summary

The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation. The main questions it aims to answer are:

1. What are the specific pharmacokinetic parameters and their variabilities for apixaban in this patient population?
2. Which clinical factors, such as kidney function or body weight, are the primary predictors of how apixaban is cleared and distributed in the body?

Participants will be asked to give consent to allow researchers to use their existing electronic outpatient medical records and previously collected blood concentration data for analysis.

Conditions

  • Non Valvular Atrial Fibrillation (nv AF)

Interventions

DRUG

Apixaban

Apixaban is administered as an oral tablet in fixed doses of 2.5 mg or 5 mg twice daily. The intervention is provided as part of standard clinical care for patients diagnosed with non-valvular atrial fibrillation. For the purposes of this pharmacokinetic analysis, the intervention requires a minimum duration of 3 consecutive days of consistent dosing to ensure that the drug has reached steady-state plasma concentrations prior to data collection.

Sponsors & Collaborators

  • Thammasat University

    collaborator OTHER

  • King Chulalongkorn Memorial Hospital

    collaborator OTHER

  • Chulalongkorn University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-04-30
Completion
2027-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07747948 on ClinicalTrials.gov